Log in

NASDAQ:TBIOTranslate Bio Stock Price, Forecast & News

+1.46 (+7.69 %)
(As of 05/25/2020 04:00 PM ET)
Today's Range
Now: $20.44
50-Day Range
MA: $12.63
52-Week Range
Now: $20.44
Volume647,410 shs
Average Volume884,653 shs
Market Capitalization$1.29 billion
P/E RatioN/A
Dividend YieldN/A
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. It has a collaboration and license agreement with Sanofi Pasteur Inc. to develop mRNA vaccines for up to five infectious disease pathogens. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 1.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.82 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:TBIO



Sales & Book Value

Annual Sales$7.80 million
Book Value$2.56 per share


Net Income$-113,290,000.00
Net Margins-859.22%


Market Cap$1.29 billion
Next Earnings Date7/29/2020 (Estimated)
OptionableNot Optionable

Receive TBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for TBIO and its competitors with MarketBeat's FREE daily newsletter.

Translate Bio (NASDAQ:TBIO) Frequently Asked Questions

How has Translate Bio's stock been impacted by COVID-19 (Coronavirus)?

Translate Bio's stock was trading at $7.43 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TBIO stock has increased by 175.1% and is now trading at $20.44. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Translate Bio?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Translate Bio in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Translate Bio.

When is Translate Bio's next earnings date?

Translate Bio is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Translate Bio.

How were Translate Bio's earnings last quarter?

Translate Bio Inc (NASDAQ:TBIO) released its quarterly earnings results on Thursday, March, 12th. The company reported ($0.48) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.36) by $0.12. The firm earned $3.89 million during the quarter, compared to analysts' expectations of $3.06 million. Translate Bio had a negative net margin of 859.22% and a negative return on equity of 63.61%. View Translate Bio's earnings history.

What price target have analysts set for TBIO?

4 analysts have issued 12-month price targets for Translate Bio's shares. Their forecasts range from $17.00 to $25.00. On average, they expect Translate Bio's stock price to reach $20.75 in the next year. This suggests a possible upside of 1.5% from the stock's current price. View analysts' price targets for Translate Bio.

What are Wall Street analysts saying about Translate Bio stock?

Here are some recent quotes from research analysts about Translate Bio stock:
  • 1. According to Zacks Investment Research, "Translate Bio, Inc. operates as a therapeutics company. It develops transformative medicines for the treatment of diseases caused by protein and gene dysfunction. Translate Bio, Inc. is based in MA, United States. " (5/15/2020)
  • 2. HC Wainwright analysts commented, "Valuation and risks to achievement of target price. Our price target of $21/share is based on an equally-weighted composite of: (a) $16.9/share, as a 35x multiple of taxed and diluted $4.33 discounted back to FY19 at 18% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $25.6/ share (discounted cash flow analysis using a 12% discount rate and 3.5% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (8/1/2019)

Has Translate Bio been receiving favorable news coverage?

Media coverage about TBIO stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Translate Bio earned a news impact score of 1.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutTranslate Bio.

Are investors shorting Translate Bio?

Translate Bio saw a drop in short interest in May. As of May 15th, there was short interest totaling 3,680,000 shares, a drop of 32.8% from the April 30th total of 5,480,000 shares. Based on an average trading volume of 477,600 shares, the days-to-cover ratio is presently 7.7 days. Approximately 8.8% of the company's stock are short sold. View Translate Bio's Current Options Chain.

Who are some of Translate Bio's key competitors?

What other stocks do shareholders of Translate Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Translate Bio investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Regeneron Pharmaceuticals (REGN), Johnson & Johnson (JNJ), Moderna (MRNA), NVIDIA (NVDA), AbbVie (ABBV), Tesla (TSLA) and Carnival (CCL).

Who are Translate Bio's key executives?

Translate Bio's management team includes the following people:
  • Mr. Ronald C. Renaud Jr., Pres, CEO & Director (Age 50)
  • Dr. Michael W. Heartlein, Chief Technology Officer (Age 60)
  • Mr. John R. Schroer C.F.A., CFA, CFO & Treasurer (Age 54)
  • Dr. Richard Wooster, Chief Scientific Officer (Age 59)
  • Mr. Paul D. Burgess J.D., Chief Legal Officer & Corp. Sec. (Age 45)

When did Translate Bio IPO?

(TBIO) raised $100 million in an initial public offering on Thursday, June 28th 2018. The company issued 7,700,000 shares at $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI acted as the underwriters for the IPO.

What is Translate Bio's stock symbol?

Translate Bio trades on the NASDAQ under the ticker symbol "TBIO."

Who are Translate Bio's major shareholders?

Translate Bio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.27%), Federated Hermes Inc. (3.64%), Camber Capital Management LP (2.81%), Rock Springs Capital Management LP (1.31%), State Street Corp (1.13%) and Geode Capital Management LLC (0.93%). Company insiders that own Translate Bio stock include Brian M Jr Gallagher and Mrl Ventures Fund Llc. View institutional ownership trends for Translate Bio.

Which major investors are selling Translate Bio stock?

TBIO stock was sold by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP, Morgan Stanley, UBS Group AG, Ensign Peak Advisors Inc, New York State Common Retirement Fund, Virtus ETF Advisers LLC, Legal & General Group Plc, and Victory Capital Management Inc.. View insider buying and selling activity for Translate Bio.

Which major investors are buying Translate Bio stock?

TBIO stock was bought by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Federated Hermes Inc., State Street Corp, JPMorgan Chase & Co., Invesco Ltd., Geode Capital Management LLC, BlackRock Inc., and ClariVest Asset Management LLC. Company insiders that have bought Translate Bio stock in the last two years include Brian M Jr Gallagher, and Mrl Ventures Fund Llc. View insider buying and selling activity for Translate Bio.

How do I buy shares of Translate Bio?

Shares of TBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Translate Bio's stock price today?

One share of TBIO stock can currently be purchased for approximately $20.44.

How big of a company is Translate Bio?

Translate Bio has a market capitalization of $1.29 billion and generates $7.80 million in revenue each year. The company earns $-113,290,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Translate Bio employs 81 workers across the globe.

What is Translate Bio's official website?

The official website for Translate Bio is www.translate.bio.

How can I contact Translate Bio?

Translate Bio's mailing address is 29 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at 617-945-7361.

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.